F S&P 500
5,119.00 +36.75 (+0.72%) F Dow Jones
38,327.00 +39.00 (+0.10%) F Nasdaq
17,744.25 +176.75 (+1.01%) E-mini Russell 2000 Index Futur
1,993.40 +0.20 (+0.01%) Petróleo
84.17 +0.60 (+0.72%) Oro
2,356.70 +14.20 (+0.61%)
ImmuCell Corporation (ICCC)
Fuera de horario:
ImmuCell Corporation
56 Evergreen Drive
Portland, ME 04103
United States
207 878 2770
https://immucell.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 74
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael F. Brigham | President, CEO, Principal Financial Officer, Treasurer, Secretary & Director | 395.24k | N/D | 1961 |
| Ms. Bobbi Jo Brockmann | VP of Sales & Marketing and Director | 323.52k | N/D | 1977 |
| Mr. A. Gustavo Scaffa | Senior Director of Quality | N/D | N/D | N/D |
| John W. Zinckgraf | Director of Product Development | N/D | N/D | N/D |
Descripción
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Gestión corporativa
La calificación ISS Governance QuickScore de ImmuCell Corporation a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
